Investing in Innovative Biopharmaceuticals
and Building Great Companies


Deep Domain

Company Building


Vatera Healthcare Partners is the dedicated healthcare venture capital and private equity investing arm of Vatera Holdings LLC. Vatera Healthcare Partners seeks to identify and develop best-in-class therapies to treat unmet medical needs and improve patients’ lives. The firm selectively invests with a long-term approach that enables strong alignment with therapeutic development cycles.

The firm deploys patient capital and targeted expertise to build great companies by leveraging its team’s collective experience in the biopharmaceutical industry and its strong network of relationships within industry and academia. Vatera Healthcare Partners makes both controlling and minority investments and is actively involved with its portfolio companies, providing hands-on operational support to our management teams.

Michael Jaharis co-founded Vatera Healthcare Partners and was an advisor to the firm until his passing in 2016. He was a legend in the industry and will be remembered for his passion for innovation, creativity and great generosity.

Vatera Healthcare Partners was founded in 2007 by Michael Jaharis, Kevin Ferro and Sundar Kodiyalam with the goal of replicating the successes of Key Pharmaceuticals and Kos Pharmaceuticals, two entrepreneurial specialty pharmaceutical companies that delivered significant value to patients and shareholders.

  • Integrity
  • Responsible Citizenship
  • Improving Patients’ Lives
  • Medical Advancement
  • Partnership
  • Innovation
  • Patience

Michael Jaharis

1928 – 2016

Michael Jaharis, a co-founder of Vatera Healthcare Partners, was a legend in the pharmaceutical industry. His passion for pharmaceutical innovation combined with a long-term vision of clinical and market needs enabled the successes with a number of pharmaceutical companies, including Key Pharmaceuticals, Kos Pharmaceuticals and Vatera Healthcare Partners’ investment in Pearl Therapeutics. With a keen understanding of their businesses, Michael continued to invest in these companies even as they faced the inevitable ups and downs of the pharmaceutical business.

Success in these pharmaceutical ventures has enabled the Jaharis family to give back through their philanthropic contributions to numerous educational, cultural and religious institutions and humanitarian causes. Generations will remember and benefit not just from Michael Jaharis’ contributions to the pharmaceutical industry, but also from his deep commitment and generosity to the causes in which he believed. Inspired by their passion for charitable causes, Michael Jaharis and his wife Mary created the Jaharis Family Foundation, Inc.

Among his many public service activities, Michael Jaharis was a board member of several prominent non-profit and educational institutions, including Trustee Emeritus of Tufts University in Boston, MA; Chairman of the Board of Overseers for the School of Medicine, Tufts University; Member of the Columbia University Medical Center Board of Visitors; Member of the Board of Overseers of the Weill Cornell Medical College and Graduate School of Medical Sciences; and Director of The Onassis Public Benefit Foundation (USA).

After serving in the U.S. Army during the Korean War, Michael Jaharis became a sales representative for Miles Laboratories while earning his law degree at night from DePaul University. Along with Phil Frost, he acquired control of Key Pharmaceuticals in 1970. Michael Jaharis developed and grew Key Pharmaceuticals from near bankruptcy into a thriving innovative pharmaceutical company that produced and marketed some of the best-selling asthma and cardiovascular products in the U.S. at the time. He turned the company around, revamped its product line and merged it with Schering-Plough in 1986 for $836 million. Michael Jaharis then launched Kos Pharmaceuticals, named for the Greek island where Hippocrates founded the science of medicine. Built on the foundation and legacy of Key Pharmaceuticals, Kos focused on the treatment of chronic diseases, developing products in the cardiovascular, metabolic and respiratory areas. Ultimately, Kos was acquired by Abbott Laboratories in 2006 for $4.2 billion.